Organ Transplantation is the medical process of replacing a person's failing or irreversibly damaged organ with a functioning organ obtained from a donor. Transplanted organs can include kidneys, livers, hearts, lungs, pancreases and intestines, with the suitability of transplantation depending on the organ, disease, recipient condition and available donor. The procedure involves much more than surgical implantation: donor assessment, organ retrieval and preservation, recipient evaluation, compatibility considerations, transplantation, immunosuppressive treatment and lifelong follow-up can all be required. Organ Transplantation can provide life-saving or life-extending treatment for selected patients with severe organ failure.
Donors can be living or deceased depending on the organ and circumstances. Living donation is commonly possible for a kidney and, in selected circumstances, part of a liver or other tissue or organ structures. Deceased donation occurs after death under legally and medically defined circumstances, with organs assessed for suitability before retrieval. Donor evaluation considers medical history, infections, organ function and other factors relevant to recipient safety. Allocation systems attempt to distribute organs according to applicable medical criteria, urgency, compatibility and other rules, which vary between jurisdictions. Organ availability is limited, making transplantation a resource constrained by both biology and logistics.
Immunological compatibility is central because a transplanted organ contains cells expressing molecules that can be recognised as foreign by the recipient's immune system. The immune response can damage the graft through mechanisms involving antibodies, T cells and other components of immunity. Compatibility considerations can include blood group and human leukocyte antigen characteristics, while crossmatching can assess whether the recipient has antibodies capable of reacting with donor cells. Even with favourable matching, rejection remains possible because biological compatibility is not absolute. Immunosuppressive medicines are therefore generally required to reduce immune-mediated graft injury.
Rejection can occur in different forms and at different times. Hyperacute rejection can occur very rapidly when pre-existing antibodies react strongly with the graft, while acute rejection can develop over a shorter period after transplantation and may involve cellular or antibody-mediated mechanisms. Chronic graft injury can develop over a longer period and may involve multiple immunological and non-immunological processes. Modern immunosuppression has substantially improved transplantation outcomes, but it also suppresses protective immune responses and can increase susceptibility to infections and certain cancers. Treatment therefore requires balancing prevention of rejection against adverse effects of immunosuppression.
Organ preservation and logistics are critical because organs deteriorate outside the body. After retrieval, organs require controlled preservation and transport before transplantation. Traditional cold storage reduces metabolic activity and delays injury, while machine perfusion technologies can circulate preservation solutions through selected organs and may provide additional assessment or preservation options. The allowable preservation interval differs among organs and circumstances. Transportation, matching, operating-room coordination and recipient readiness must be synchronised because an organ cannot be treated as an ordinary stored medical product with unlimited shelf life.
Recipient evaluation is comprehensive because transplantation involves major surgery and long-term immunological and medical management. Clinicians assess the underlying disease, other organ function, infection status, cardiovascular and other surgical risks, adherence considerations and the likelihood that transplantation will provide meaningful benefit. After transplantation, recipients require regular monitoring of graft function, medication levels where relevant, infections and complications. Immunosuppressive regimens commonly combine medicines with different mechanisms and may be adjusted over time according to rejection risk, toxicity and graft function.
Organ Transplantation has important ethical and legal dimensions concerning consent, deceased donation, living donation, allocation and the prevention of exploitation or coercion. Donation systems differ internationally, including approaches to consent and allocation. Living donors require independent assessment of risks and voluntary decision-making because the donor undergoes medical intervention without receiving the direct therapeutic benefit experienced by the recipient. Allocation policies must balance competing principles such as urgency, compatibility, expected benefit, fairness and waiting time. These issues require transparent governance rather than purely individual clinical decisions.
Organ Transplantation has transformed the management of otherwise terminal or severely disabling organ failure, but it remains constrained by donor availability, surgical complexity, immune rejection, medication toxicity, infection, graft failure and long-term follow-up requirements. Successful transplantation is therefore a continuing medical process rather than a single operation. Advances in organ preservation, immunosuppression, donor selection, living donation and other technologies continue to expand possibilities, while the fundamental challenges of immune compatibility, organ scarcity and equitable allocation remain central to the field.
